Phosphoinositide 3-Kinase Inhibitor (PI3k) Inhibitors - Pipeline Insights, 2016

  • ID: 3774307
  • Drug Pipelines
  • 160 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • Bayer Schering Pharma
  • Genentech
  • Novartis
  • MORE
“Phosphoinositide 3-Kinase Inhibitor (PI3k) Inhibitors-Pipeline Insights, 2016” provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Phosphoinositide 3-Kinase Inhibitor (PI3k) Inhibitors.

Note: This report will be delivered to the client in 48 hours

Report Highlights:
- The new report, provides a Phosphoinositide 3-Kinase Inhibitor (PI3k) Inhibitors Landscape across the globe
- The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
- Coverage of the Phosphoinositide 3-Kinase Inhibitor (PI3k) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for PI3k Inhibitors and also provide company profiling
- Pipeline products coverage based on various stages of development from NDA filings to discovery.
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer Schering Pharma
  • Genentech
  • Novartis
  • MORE
Table of Contents

- Overview
- Epidemiology
- Market Scenario
- Pipeline Therapeutics
- An Overview of Pipeline Products for PI3k Inhibitors
- Therapeutics under Development by Companies
- Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Mid Stage Products (Phase II)
- Comparative Analysis
- Product Description
- Product Development Activities
- Early Stage Products (Phase I and IND)
- Comparative Analysis
- Discovery and Pre-clinical stage Products
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Discontinued Products
- Dormant Products
- Companies involved in Therapeutics Development
- Appendix
- Methodology
- Consulting Services
- Disclaimer
- Report Purchase Options
- About us
- Contact Us

List of Tables

Table 1: Number of Products Under Development, 2016
Table 2: Number of Products under Development by Companies, 2016
Table 3: Last Stage Products (Phase III and Filed), 2016
Table 4: Mid Stage Products (Phase II), 2016
Table 5: Early Stage Products (Phase I and IND), 2016
Table 6: Phase 0 stage Products , 2016
Table 7: Discovery and Pre-clinical Stage Products , 2016
Table 8: Assessment by Monotherapy Products,2016
Table 9: Assessment by Route Of Administration, 2016
Table 10: Assessment by Stage and Route Of Administration, 2016
Table 11: Assessment by Molecule Type, 2016
Table 12: Assessment by Stage and Molecule Type, 2016
Table 13: Discontinued Products, 2016
Table 14: Dormant Products, 2016
Table 15: Companies Involved in Therapeutic Development, 2016

List of Figures

Figure 1: Number of Products under Development for BET Inhibitors ,2016
Figure 2: Late Stage Products (Filed and Phase III),2016
Figure 3: Mid Stage Products (Phase II),2016
Figure 4: Early Stage Products (Phase I and IND),2016
Figure 5: Discovery and Pre-clinical Stage Products, 2016
Figure 6: Assessment by Monotherapy Products, 2016
Figure 7: Assessment by Combination Products, 2016
Figure 8: Assessment by Route of Administration, 2016
Figure 9: Assessment by Stage and Route of Administration, 2016
Figure 10: Assessment by Molecule Type, 2016
Figure 11: Assessment by Stage and Molecule Type, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Genentech
- Novartis
- Bayer Schering Pharma
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll